Strykagen Corporation is a biopharmaceutical company developing protein and small molecule therapeutics to treat rare muscle diseases. As of 2014, Strykagen has several candidates in pre-clinical development for the treatment of Duchenne muscular dystrophy, Becker muscular dystrophy, Merosin deficient congenital musuclar dystrophy, and limb girdle Muscular Dystrophies. Strykagen also has discovered and is developing a biomarker usable in the treatment of muscular dystrophy. Strykagen has exclusive licenses for its underlying technology which works by stabilizing the myomatrix, thus preventing disease progression.
